CorVel (CRVL) Q4 2026 earnings review
Growth Rebounds and AI Margins Flow to the Bottom Line
CorVel ended FY26 by successfully snapping its mid-year revenue deceleration. After dipping to an anemic 3% growth in Q3, Q4 top-line revenue rebounded to 7% YoY ($249M). More importantly, the company's aggressive integration of Agentic AI is visibly working: operating leverage is accelerating. EPS jumped 20% to $0.61, outpacing revenue growth by nearly 3-to-1. With zero debt and cash climbing to $233M, CorVel is aggressively buying back stock, spending a record $20.1M in the quarter. The only major blind spot for investors remains management's strict refusal to break out segment financials.
🐂 Bull Case
Gross margins expanded to over 25% (up from 23.3% last quarter) as investments in automation and the CorVel Connected platform lower administrative burdens and accelerate revenue realization cycles.
With $233M in cash, zero debt, and highly cash-generative operations, CorVel is immune to current rate pressures while scaling up its share repurchase program sequentially.
🐻 Bear Case
While Q4 was a sequential improvement over Q3, the 7% YoY revenue growth is still noticeably decelerating compared to the 11-12% growth rates seen in late FY25 and early FY26.
Management continues to actively refuse providing quantitative breakdowns for its patient management versus network solutions segments, forcing investors to trust the blended outcome without seeing the underlying unit economics.
⚖️ Verdict: 🟢
Bullish. The Q3 growth scare appears transitory. By utilizing Agentic AI to counteract structural industry labor shortages and pricing pressure, CorVel is translating mid-single-digit sales growth into robust, 20% bottom-line expansion.
Key Themes
Agentic AI is Driving Real Operating Leverage
Management's heavy promotion of 'Agentic AI' is showing up in the numbers. By using AI for real-time data integration, supervisory support, and decision-making augmentation in the CorVel Connected platform, the company is absorbing commercial health pricing pressures. Gross profit grew 9% on just 7% revenue growth, proving that automation is successfully reducing service delivery costs.
The 'Black Box' Reporting Approach
A major governance red flag persists: CorVel refuses to provide detailed financial segment reporting. When pressed by analysts in prior quarters for color on patient management vs. network solutions, management bluntly stated they operate as a 'single segment' and it is company policy not to break it out. For a company navigating specific headwinds in Commercial Health (CERiS pricing pressure), this lack of transparency masks the health of individual product lines.
Accelerating Capital Returns
CorVel is using its debt-free balance sheet to aggressively lean into share repurchases. Buybacks have been steadily accelerating throughout FY26: $9.6M in Q1, $12.8M in Q2, $13.4M in Q3, and jumping to $20.1M in Q4. This financially engineered EPS support is sustainable given the $233M cash pile.
CERIS Division Tailwinds
The healthcare division is benefiting heavily from rising regulatory scrutiny and a payer-driven shift toward payment accuracy. The integrated prepay and post-pay platforms landed 'multiple large payer sales with enterprise-scale implementations' this quarter. Record FCA recoveries in healthcare ($5.7B reported prior quarter) serve as a potent macro driver for their fraud and waste services.
Long-Term Revenue Deceleration Must be Watched
Despite Q4's stabilization, the broader trend is decelerating. Revenue growth cooled from 12% in late FY25 to 7% currently. The demographic shifts (labor shortages in workers' comp) and elevated pricing demands from payer partners mean top-line expansion is getting fundamentally harder to secure.
Other KPIs
Accelerating. Up 19% YoY from $33.3 million. Operating margin improved sharply to 16.0% (from 13.5% in the troubled Q3). G&A expenses actually decreased to $23.3M from $24.6M YoY, demonstrating absolute cost control rather than just relative leverage.
Up 28% from $92.1 million a year ago. Management attributed this in prior quarters to elevated CapEx largely driven by software development and licenses to support their AI and Care MC platform build-outs.
Guidance
Stable. CorVel continues its strict policy of not issuing specific forward financial targets for revenue or EPS. The only forward-looking statements provided relate to qualitative expectations of 'improved productivity resulting from automation and augmentation.'
Key Questions
Drivers of Q4 Revenue Rebound
Revenue growth reaccelerated to 7% after dropping to 3% in Q3. What specific product lines or new client implementations drove this turnaround, and is 7-10% the normalized expectation moving forward?
Agentic AI ROI
You highlight Agentic AI and the CorVel Connected platform as margin drivers. How much of the absolute G&A decline this quarter (down $1.3M YoY) is directly attributable to AI automation vs. traditional headcount rationalization?
Segment Transparency
With the CERIS division signing multiple enterprise implementations, why maintain the policy of withholding segment financials? How should investors model the separate growth trajectories of the P&C and Health divisions?